On the same line, CDK4 inhibitor, already in clinical use as anti-cancer treatment, induces TIF-IA degradation, NF-κB recruitment to the nucleolus and impairs the NF-κB -dependent expression of anti-apoptotic genes (Thoms et al., 2007b). The gene discussed is NFKB1; the disease is cancer.